

RESEARCH

Open Access

Intracerebroventricular injection of leukotriene B₄ attenuates antigen-induced asthmatic response via BLT1 receptor stimulating HPA-axis in sensitized rats

Shui-Juan Zhang^{†1,2}, Yang-Mei Deng^{†1}, Yi-Liang Zhu¹, Xin-Wei Dong¹, Jun-Xia Jiang¹ and Qiang-Min Xie^{*1}

Abstract

Background: Basic and clinical studies suggest that hypothalamic-pituitary-adrenal (HPA) axis is the neuroendocrine-immune pathway that functionally regulates the chronic inflammatory disease including asthma. Our previous studies showed corresponding changes of cytokines and leukotriene B₄ (LTB₄) between brain and lung tissues in antigen-challenged asthmatic rats. Here, we investigated how the increased LTB₄ level in brain interacts with HPA axis in regulating antigen-induced asthmatic response in sensitized rats.

Methods: Ovalbumin-sensitized rats were challenged by inhalation of antigen. Rats received vehicle, LTB₄ or U75302 (a selective LTB₄ BLT1 receptor inhibitor) was given via intracerebroventricular injection (i.c.v) 30 min before challenge. Lung resistance (R_L) and dynamic lung compliance (C_{dyn}) were measured before and after antigen challenge. Inflammatory response in lung tissue was assessed 24 h after challenge. Expression of CRH mRNA and protein in hypothalamus were evaluated by RT-PCR and Western Blot, and plasma levels of adrenocorticotrophic hormone (ACTH) and corticosterone (CORT) were measured using the ELISA kits.

Results: Antigen challenge decreased pulmonary function and induced airway inflammation, evoked HPA axis response in sensitized rats. Administration of LTB₄ via i.c.v markedly attenuated airway contraction and inflammation. Meanwhile, LTB₄ via i.c.v markedly increased CORT and ACTH level in plasma before antigen challenge, and followed by further increases in CORT and ACTH levels in plasma after antigen challenge in sensitized rats. Expression of CRH mRNA and protein in hypothalamus were also significantly increased by LTB₄ via i.c.v in sensitized rats after antigen challenge. These effect were completely blocked by pre-treatment with BLT1 receptor antagonist U75302 (10 ng), but not by BLT2 antagonist LY255283.

Conclusions: LTB₄ administered via i.c.v down-regulates the airway contraction response and inflammation through activation of the HPA axis via its BLT1 receptor. This study expands our concept of the regulatory role of intracranial inflammatory mediators in inflammatory diseases including asthma. The favourable effects of LTB₄ on the HPA axis may help to explain the phenomenon of self-relief after an asthmatic attack.

Background

Central nervous system (CNS) and neuroendocrine-immune systems (NEI) are the two major systems which respond adaptively to the numerous challenges to maintain the physiological homeostasis. The adaptive responses could be impaired by some physical and psychological stressors in neuroendocrine-immune feedback system. Such dysfunction could also contribute to the

* Correspondence: xieqm@zju.edu.cn

¹ Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, Medical Science College of Zhejiang University, Hangzhou, China

[†] Contributed equally

Full list of author information is available at the end of the article

pathogenesis of allergic or autoimmune diseases [1]. The studies on the cross-talk between neuroendocrine and immune systems added further evidences that interactions among the neural, neuroendocrine and immune systems are bidirectional [1-3]. Recent studies have shown that this bidirectional cross-talk is based on the secretion of pro-inflammatory factors including mediators and cytokines, hormones, neurotransmitters and neuropeptides [4-6]. The hypothalamic-pituitary-adrenal (HPA) axis is the major pathway in NEI, hypothalamus secretes corticotropin releasing hormone (CRH) when the HPA axis is activated. This molecule travels to the anterior pituitary gland, which responds to its presence by secreting a pulse of adrenocorticotropin hormone (ACTH). The ACTH signal is carried through the peripheral circulation to the adrenal glands, which synthesize and release cortisol and lead to reduction of inflammation.

Leukotriene (LT) B₄ is a product of the action of LTA₄ hydrolase (LTA₄-H) on LTA₄ in 5-lipoxygenase (5-LO) pathway. It is a potent leukocyte chemoattractant and activator, which plays an important role in modulating immune and inflammatory responses [7]. An early study showed that LTB₄ increases CRH secretion in explanted and cultured hypothalamus via autocrine/paracrine or as endocrine factor [8]. Further studies found that inflammatory mediator such as IL-1, IL-6 can activate the HPA axis and regulate the inflammatory response in periphery [9]. From previous work, we found that the changes of Th1/Th2 paradigm (ratio of interferon [IFN]-gamma/interleukin [IL]-4 decreased) [10], and the content of LTB₄ in the cerebral cortex increases corresponding to their changes in bronchoalveolar lavage fluid (BALF) or lung tissue in inflammatory status of asthmatic rats [11]. Also, the expression of 5-LO and LTA₄-H mRNA in cerebral cortex of asthmatic rats are significantly higher than those of control rats [12]. All these findings indicate that the changes of these proinflammatory mediators in the CNS may have pathophysiologic effects in asthmatic rats.

So far, it is unclear how LTB₄ in the CNS regulates inflammation in lung tissue of asthma. Based on these studies, we postulate that the increase of LTB₄ in brain activates NEI, which may regulate asthmatic response in rats. To explore this hypothesis, rats were actively sensitized with ovalbumin (OVA), and LTB₄ was administered via intracerebroventricular injection (i.c.v). The pulmonary function and inflammatory cell infiltration in lung were evaluated. Meanwhile, the HPA axis activity was also explored by measuring CRH mRNA and protein expression in hypothalamus, corticosterone (CORT) and ACTH level in plasma during antigen challenge in sensitized rats.

Methods

Animal and study design

Sprague-Dawley (SD) rats of either sex weighing 180~200 g were purchased from Laboratory Animal Center in Medical Science College of Zhejiang University (Grade II, Certificate No. 220010014). All animals were housed in Plexiglas cages and kept on a 12/12 h light-dark cycle in temperature and humidity controlled rooms, standard laboratory food and water were provided ad libitum. Food was withheld 8 hours before the experiments, with free access to water. Unless otherwise indicated, Animal treatments were strictly in accordance with the China Community Guidelines for the Use of Experimental Animals and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were assigned to different treatments, Vehicle-sham group was as normal control, ovalbumin (OVA) sensitized and challenged rats were treated as asthmatic model (Vehicle-OVA), the effects of LTB₄ (LTB₄-OVA) via i.c.v on asthmatic rats were evaluated. And U75302, the selective BLT1 receptor antagonist, was administered via i.c.v alone (U75302-OVA) or 5 min before LTB₄ dosing (U75302-LTB₄-OVA).

Sensitizing procedures

To sensitize the rats, 1 mg OVA (Grade V, Sigma Chemical Co., St. Louis, MO) absorbed in 100 mg aluminium hydroxide adjuvant in 1.0 ml saline. Each rat was intraperitoneally injected (i.p) with 0.5 ml, and subcutaneously injected (s.c) with 0.05 ml/site at four footpads (4 sites), neck (one site), back (3 sites), and two groins (2 sites), respectively. Then, every rat was injected (i.p) with 1 × 10¹⁰ bordetella pertussis adjuvant (Shanghai Institute of Biological Products, China) on experiment day 0. Normal control (vehicle-sham) rats were injected with only aluminium hydroxide adjuvant in saline following the same protocol. At day 14 after sensitization, the rats were placed in a 45 cm × 45 cm × 15 cm plastic box and challenged by exposure to an aerosol of OVA (20 mg/ml in saline), which was generated in a jet nebulizer (particle size 1-5 μm; BARI, MASTER, Germany) for 20 min, and repeated daily to day 21 after sensitization. Vehicle-sham rats were similarly exposed to an aerosol of saline.

Intracerebroventricular injection

After 10% chloral hydrate (3 ml/kg i.p) anaesthesia, the animal's head was fixed in a stereotaxic apparatus (SR-6N, Narishige, Japan). The procedure of i.c.v. injection was in accordance with rat brain graph described by George Paxious and Charles Watson, and with minor improvement as described by Mauser et al [13]. In brief, a midline incision was made from a point just posterior to the eyes to about 3 cm caudal, and the overlying connective tissue was removed to expose the skull. A small hole

(about 2 mm in diameter) was opened perpendicularly to the skull, -1.0 or -1.5 mm anterior and 1.5 mm lateral to the bregma by using a dental drill (Minimo, Japan). A stainless steel guide cannula (internal diameter, 0.5 mm; length, 1.5 cm) was then slowly and vertically lowered to a depth of 3.8 mm from the dura into lateral ventricles. The guide cannula was then held in place by dental cement (oral cavity drugs and materials of Wuhan University, China) with a small anchor screw. The scalp was sutured and the animals were left to recover for 1 week before the first antigen challenge. All injections through the i.c.v. were made with a Hamilton syringe (Reno, NV, U.S.A.) and in a 10 μ l volume of artificial CSF. In vehicle-sham or LTB₄-OVA group, vehicle 10 μ l or LTB₄ 10 ng (Sigma Chemical Co., St. Louis, MO) (Cayman Chemical) was administered via i.c.v. 30 min before the antigen challenge from day 14 to day 21. In the U75302-LTB₄-OVA group, an extra dose of U75302 10 ng was administered via i.c.v. 5 min before LTB₄ dosing.

Measurement of pulmonary function

The lung function was assessed 30 min before and after LTB₄ i.c.v. on day 21 after sensitization as described previously [14]. Briefly, each anaesthetized rat was placed supine inside a Plexiglas whole-body plethysmograph. The flow rate was monitored with a Fleisch tube connected to the airway in a pressure transducer. Changes in lung volume were measured by detecting pressure changes in the plethysmographic chamber through a port in the connecting tube with a pressure transducer. To measure pleural pressure, a needle (No. 16) with a multi-holed tip was directly inserted into the pleural cavity (between fourth and fifth rib at left thorax) through a port in the connecting tube with a differential pressure transducer. Transpulmonary pressure was calculated as the difference between mouth and pleural pressure. All signals of pressure transducers were continuously computed (MedLab, Nanjing Biotech Instruments, China) by fitting flow, volume, and pressure to an equation of motion. For antigen challenge, OVA 20 mg/ml dissolved in saline aerosolized by a jet nebulizer (BARI Co. Ltd, Germany) for 5 min. The respiratory waveform was monitored for 15 min and maximal changes from baseline for each parameter were recorded by the MedLab. The results were shown as airway resistance (R_L) and dynamic lung compliance (C_{dyn}) value before and after antigen challenge.

Preparation of bronchoalveolar lavage fluids

Twenty-four hours after the final OVA challenge, rats were anesthetized with urethane (2 g/kg, i.p.). Bronchoalveolar lavage fluids (BALF) were obtained via tracheal tube by washing of the right lung with 1 ml of sterilized saline containing 1% bovine serum albumin (BSA) and 5

IU/ml heparin for three times. The total number of cells in the BALF was counted. The BALF was centrifuged for 10 min at 400 \times g at 4°C. Two hundred cells from the cell suspension were stained by Wright-Giemsa and classified using a light microscope. The results were expressed as the numbers of each type of cell population in 1 ml of BALF.

Lung histopathology

The left lung was fixed in 10% neutral formalin for 7 days. Sections of 5 μ m thickness were prepared and stained with hematoxylin-eosin (H&E). To determine the severity of inflammatory cell infiltration, peribronchial eosinophil cell number was blindly counted and the severity was evaluated by a 5 point scoring system described previously [15]. Briefly, the scoring system was 5-marked, 4-moderate, 3-medium, 2-mild, 1-minimal and 0-no eosinophil cells.

ACTH and CORT assay

Blood samples were collected in heparin-coated tubes via the tail vein 30 min before, 30 min after LTB₄ i.c.v., and 30 min after final antigen challenge. Blood samples were centrifuged at 2000 \times g to separate plasma at 4°C for 15 min. All samples were stored at -80°C until analysis. The levels of ACTH and CORT in plasma were measured using a commercial ELISA kit (USCN-LIFE™, China) by following the manufacturer's instructions.

Isolation of hypothalamus

Rats were euthanized and then decapitated 24 h after the final antigen challenge. Hypothalamus was dissected with the following limits: anterior border of the optic chiasm, anterior border of the mamillary bodies, and lateral hypothalamic sulci. The depth of dissection was approximately 3 mm. The hypothalamus was then quickly frozen in liquid nitrogen and preserved at -80°C for extraction of RNA or protein.

Reverse transcription and polymerase chain reaction

Total RNA was isolated with TRIzol Reagent (Invitrogen, USA). First-strand cDNA was generated from 4 μ g of total RNA using oligo-dT to prime the reverse transcription according to the supplied protocol (Invitrogen). PCR were performed using commercial PCR reagents Kit (TaKaRa) in a gradient thermal cycler PCR machine (Eppendorf, Germany). Rat CRH was amplified using primers 5'-TCACCTTCCACCTTCTGAGG-3' and 5'-GGAAATGAAATGTTGCGCTT-3' (317 bp, intron spanned) for 35 cycles (94°C 30 s, 58°C 45 s, 72°C 45 s). Primers for rat GAPDH were 5'-ACCACCATGGA-GAAGGCTGG-3' and 5'-CACAGTGTAGCCAG-GATGC-3' (528 bp, intron spanned) for 28 cycles (94°C 30 s, 58°C 30 s, 72°C 60 s). Aliquots of polymerase chain reaction products were separated by electrophoresis on

1.5% agarose gels and visualized with ethidium bromide, and the PCR product bands were quantified by using UVP Gel Documentation system (UVP, Upland, CA). Results were expressed as a ratio of densitometry value of CRH to that of GAPDH.

Western Blot

CRH protein expression in hypothalamus was assessed as described by Meloni EG et al [16]. 20 µg protein/lane (determined by protein assay; Eppendorf Biophotometer, Germany) was loaded onto a 6-well, 12% Bis-Tris gel (Invitrogen) and electrophoresed in 1 × 2-N-morpholinoethane sulfonic acid (MES)-SDS running buffer (Invitrogen). After electrophoretic transfer, the polyvinylidene fluoride (PVDF) membranes were cut to isolate the beta-actin band as well as the lower molecular weight CRH band. Membranes were incubated in blocking buffer (5% non-fat dry milk in PBS and 0.1% Tween 20; PBS-T) overnight at 4°C and then incubated with either polyclonal rabbit anti-CRH (1:200; Santa Cruz Biotechnology) or rabbit anti-beta-actin (1:1,000; Cell Signaling Technology) antibody diluted in PBS-T for 2 h at room temperature. After incubation in secondary antibody (HRP-conjugated goat anti-rabbit IgG, 1:5000; Li-cor Biosciences) diluted in blocking buffer for 2 h, immunoreactivity was visualized with chemiluminescence using an Image Station (Odyssey, American Gene Co.). Specific CRH band was determined by the synthetic rat CRH (rCRH, American peptide Company). Immunoblots were quantified by image analysis (UVP, Upland, CA) and data were expressed as a ratio of densitometry value of CRH to that of beta-actin.

Statistical analysis

Numerical data were presented as means ± S.D. Statistical calculations were performed using SigmaStat software (SigmaStat 2.0, SPSS Inc., Chicago, IL, USA), ANOVA and Student-Newman-Keuls multiple comparisons test were used to calculate the significance of differences of respiratory function, inflammatory cells in BALF, levels of CORT and ACTH in plasma, and expression of CRH in hypothalamus. A non-parametric test, the Mann-Whitney U-test, was used to compare differences in eosinophil infiltration in airway. Significance was assessed at the $P < 0.05$ level.

Results

The changes of airway resistance and dynamic lung compliance

Compared with the baseline values, saline inhalation did not show effects on the airway resistance (R_L) and dynamic lung compliance (C_{dyn}) in both vehicle-sham rats and OVA-sensitized rats (data not shown). Bronchial challenge of OVA induced significant increase of R_L and

decrease of C_{dyn} with maximal response at 4~5 min in the vehicle-OVA group. These responses were suppressed by treatment of LTB₄ via i.c.v as shown in the LTB₄-OVA group ($P < 0.01$), but not by U75302. However, U75302 at 10 ng via i.c.v. completely blocked the inhibitory effects of LTB₄ on antigen-induced increase of R_L and decrease of C_{dyn} in LTB₄-U75302-OVA group (Fig. 1).

Airway inflammation

To further study the effect of LTB₄ i.c.v on antigen-induced airway inflammation, we evaluated the inflammatory cell infiltration in OVA sensitized rats. 24 h after the final OVA challenge, inflammatory cells including polymorphonuclear (PMN) cells (eosinophils and neutrophils) and monocytes (lymphocytes and macrophages) in BALF were counted. The total inflammatory cells in BALF of vehicle-OVA rats was 6-fold greater than that in vehicle-sham rats. LTB₄ 10 ng (i.c.v) significantly decreased the total inflammatory cells in BALF. Classification of these inflammatory cells showed that in vehicle-OVA rats, numbers of PMN and monocytes in the BALF increased 11.6 and 4.2 fold, respectively, as compared with those observed in vehicle-sham rats (Fig. 2). LTB₄ 10 ng (i.c.v) significantly decreased PMN in BALF. U75302 10 ng itself (i.c.v) did not alter the infiltration of inflammatory cells in airways, but almost fully blocked inhibitory effects of LTB₄ on the inflammatory cell numbers in BALF ($P < 0.01$).

Eosinophil infiltration in lung tissues

Effect of LTB₄ via i.c.v on antigen-induced inflammatory response was also evaluated by lung histopathology. Lung tissues were harvested 24 h after the final OVA challenge. The vehicle-OVA rats exhibited an obvious eosinophil cell infiltration into the peribronchiolar and perivascular connective tissues as compared with vehicle-sham rats. LTB₄ 10 ng (i.c.v) markedly inhibited the OVA-induced eosinophil infiltration as compared with vehicle-OVA rats ($P < 0.01$), and the inhibitory effect of LTB₄ was blocked by U75302 (Fig. 3).

Plasma CORT and ACTH concentrations

To further test the hypothesis that LTB₄ exert its inhibitory effect via activation of HPA axis, we measured the level of CORT and ACTH in plasma 30 min before and after LTB₄ administration, and 30 min after antigen challenge. Plasma CORT and ACTH concentrations did not differ significantly before LTB₄ i.c.v treatment in all groups (Fig. 4). LTB₄ via the i.c.v markedly increased plasma CORT and ACTH secretion rate in the LTB₄-OVA group to 2.4 and 3.2 folds of the basal rate, respectively. However, U75302, at the dose of 10 ng (i.c.v), markedly blocked LTB₄ induced increase of secretion of




Figure 1 LTB₄ via i.c.v attenuates the antigen-induced changes of pulmonary function in rats, and U75302 blocks the inhibitory effect of LTB₄. On day 21 after ovalbumin sensitization, rats were challenged for 5 min with aerosolized 2% ovalbumin and the airway resistance (R_L) (A) and dynamic lung compliance (C_{dyn}) (B) were measured before and 5 min after the antigen challenge. Data are expressed as the mean \pm S.D of vehicle-sham (n = 8), vehicle-OVA (n = 10), LTB₄-OVA (n = 9), U75302-OVA (n = 9) and U75302-LTB₄-OVA (n = 10). ^{##} $P < 0.01$ vs the vehicle-sham group; ^{**} $P < 0.01$ vs the vehicle-OVA group; ^{††} $P < 0.01$ vs the LTB₄-OVA group.

CORT and ACTH in plasma ($P < 0.01$). Interestingly, plasma CORT and ACTH concentrations in all treatment groups increased significantly 30 min after antigen challenge, and LTB₄ at 10 ng (i.c.v) additionally increased the concentration of plasma CORT by 92.6% ($P < 0.01$) and





Figure 2 LTB₄ via i.c.v attenuates the antigen-induced increases of inflammatory cell in the BALF, and U75302 blocks the inhibitory effect of LTB₄. Total inflammatory cells in BALF were counted, and cell classification was performed on a minimum of 200 cells to classify monocytes (lymphocytes and macrophages) and polymorphonuclear cells (eosinophils and neutrophils) 24 hr after the final antigen challenge. Data are expressed as the mean \pm S.D of vehicle-sham (n = 8), vehicle-OVA (n = 10), LTB₄-OVA (n = 9), U75302-OVA (n = 9) and U75302-LTB₄-OVA (n = 10). ^{##} $P < 0.01$ vs the vehicle-sham group; ^{**} $P < 0.01$ vs the vehicle-OVA group; ^{††} $P < 0.01$ vs the LTB₄-OVA group.

ACTH by 71.5% ($P < 0.01$) after antigen challenge as compared with that after LTB₄ i.c.v treatment. Furthermore, compared with LTB₄-OVA group, pretreatment with U75302 at 10 ng also suppressed LTB₄ i.c.v induced increase of CORT and ACTH after antigen challenge. On contrast, LY255283, a BLT2 antagonist (Cayman Chemical), did not significantly block LTB₄ effects even at a large dose (50 ng/kg, i.c.v) (data not shown). Compared with the vehicle-OVA group, U75302 alone at 10 ng (i.c.v) only decreased CORT ($P > 0.05$) and ACTH ($P > 0.05$) level for around 15% to 20% in plasma after antigen challenge in U75302-OVA group when comparing with vehicle-OVA group.

Expression of CRH mRNA and protein in hypothalamus


Expression of CRH mRNA and protein in hypothalamus were evaluated in this study. We found that LTB₄ alone via the i.c.v or OVA challenge alone markedly increased CRH mRNA and protein expression in sensitized rats. Additionally, LTB₄ via the i.c.v further increased OVA challenge-induced CRH mRNA and protein expression in hypothalamus in sensitized rats (Fig. 5A and 5B). Furthermore, compared with LTB₄-OVA group, U75302 alone decrease around 15% or 30% of CRH mRNA and




protein expression but was not statistically significant. Pretreatment with U75302 at 10 ng via i.c.v suppressed LTB₄-induced increase of CRH mRNA and protein expression in antigen challenged sensitized rats. On contrast, LY255283 did not significantly block the effects of LTB₄ even at a large dose (50 ng/kg, i.c.v).

Discussion

Recent studies have emphasized an important role of inflammatory mediators in the regulation of neuroendocrine pathways during immune challenge and in pituitary hormone secretion [17]. Particular emphasis is placed on the cross-talk between inflammation and the HPA axis. Studies have shown that inflammatory cytokines (IL-1, IL-6 etc) activate the HPA axis with the increase of secretion of cortisol, which in turn suppresses the inflamma-



tory and immune reaction [9]. During antigen-mediated activation, CD4⁺ and CD8⁺ lymphocytes are able to produce hormones like ACTH, growth hormone (GH), thyroid stimulating hormone (TSH) and gonadotropins [18]. More directly, an antigenic challenge delivered either via the i.c.v or i.v routes evokes an increased HPA axis response in dogs that sensitized with IgE via the i.c.v



route [19]. The activation of the HPA axis is also observed in allergic rhinitis during nasal provocation and in cutaneous inflammatory disease [20,21]. Thus, the activated HPA axis inhibits the inflammation via increased cortisol. Conversely, the deregulation of the HPA axis and inability to increase glucocorticoid production in

response to stress is associated with increased airway inflammation with mechanical dysfunction of the lungs in asthma. For example, in CRH-knockout mice, the airway inflammation increased and lung mechanical function decreased with the increased IL-4 and IL-13 levels, and impaired adrenal responses to stress in asthmatic mice [22]. This is also in agreement with the clinical observation that stressful life events increase the risk of a new asthma attack [23]. All these studies indicate that the crosstalk between inflammatory mediator and HPA axis regulate asthma.

Evolving evidence indicates that LTB₄ has an important role in the development of asthma [24], and LTB₄ mediated effects are thought through two G-protein coupled receptors (GPCRs), BLT1 (high affinity) and BLT2 (low affinity) [25,26].

Interestingly, particularly high levels of neuronal 5-LO expression and LTB₄ content have been identified in CNS upon challenge with a variety of stimuli [27,28]. Our previous study found that antigen challenge induces the expression of 5-LO and LTA₄H mRNA and LTB₄ levels in brain after antigen challenge in sensitized rats. And the glucocorticoid examethasone inhibited the 5-LO and LTA₄-H mRNA expression in cerebral cortex in the asthmatic rats [12]. In this study, we further evaluated the functional effect of LTB₄ in brain through exogenously injection of LTB₄ via i.c.v. We observed that antigen challenge or LTB₄ injection via i.c.v alone activates the HPA axis, while combination of both further increases the HPA axis activation, which is manifested by the increased CRH mRNA and protein expression in hypothalamus, and increased ACTH and CORT level in plasma of sensitized rats. The increased HPA activation was accompanied by the alleviation of airway inflammation and improvement of lung mechanical function in sensitized rats. Using the selective receptor antagonist, we found that pretreatment of BLT1 receptor antagonist U75302 via i.c.v, but not BLT2 antagonist, completely suppressed LTB₄ induced effects. In fact, the functional effect of LTB₄ via i.c.v on HPA axis and peripheral asthmatic symptom in this study was supported by other studies. For example, it was found eicosanoids including LTB₄ induces CRH secretion in explanted and cultured hypothalamus from rat [8]. And the deficiency of CRH worsen the airway inflammation and lung mechanical dysfunction in sensitized mouse [22]. Base on these and aforementioned observations, we postulate that the increase of LTB₄ level in brain induced by antigen challenge may acts as an immunomodulator, stimulates HPA axis activity via its selective BLT1 receptor, and the final increased cortisol level attenuates antigen-induced airway contraction and inflammation in the asthmatic model of rats.

It appears that different mechanisms in acute vs chronic stress as the stimulator to the HPA axis influence the inflammatory responses of the airway in asthma. It is supposed that acute stress causes the activation of HPA axis and consequent cortisol release, leading to reduction of airway inflammation. However, in chronic stress condition, after continuous prolonged or intermittent stimulation, HPA axis activity is suppressed and its anti-inflammatory effect is reduced [23]. For example, studies found that acute stress or stress-induced TNF- α or P substance production enhances airway reactivity or inflammation in OVA sensitized mice [29,30]. In adult mice, exposure to short-term stress (3 days) decreases the inflammatory cell number in BALF, while the inflammatory cytokine level increased after a long-term exposure (7 days) [31]. In our study, continuous antigen attack (7 days) to sensitized rats is supposed to be the chronic stressor, but we observed the increase of CRH expression in hypothalamus, ACTH and CORT level in plasma after antigen challenge, which is contradictory to the opinion of chronic stress inhibiting the HPA axis. Our postulation is that the antigen attack still provokes the acute airway response in established disease state, which may act as an acute stressor to activate the NEI system and regulate the HPA axis response.

We did not find significant differences in airway inflammation and lung mechanical function in sensitized rats treated with U75302 alone via i.c.v., which may suggest that the endogenous intracerebral LTB₄ activity does not normally play a large role in modulating airway inflammation in this model. Notably, we observed a mild decrease (around 15%-30%) in CRH expression in hypothalamus or ACTH and CORT level in plasma after BLT1 was blocked by U75302 after antigen challenge. We postulate that the increased endogenous LTB₄ induced by antigen challenge may mildly activate the HPA axis, but this activation of the HPA axis may be not enough to antagonize peripheral inflammation in this asthmatic model. Another possible explanation is that the functional effect of increased endogenous LTB₄ induced by antigen challenge may be balanced by other mediators or cytokines in brain. For example, the levels of Th2- (e.g. IL-4, IL-13) and Th1- cytokines (e.g. INF- γ) during asthmatic attack in brain are also changed after antigen challenge. Further studies are needed to clarify how the HPA axis response to the change of asthma-related cytokines and other inflammatory mediators, and how the HPA axis communicates with neural and endocrine networks as well as their signal pathways in regulating peripheral allergic response.

Conclusions

This study finds that administration of LTB₄ via i.c.v. activates HPA axis via the BLT1 receptor, which may contrib-

ute to the attenuation of the airway inflammation and decreased lung function in asthmatic status. This study expands our concept of the regulatory role of intracranial inflammatory mediators in inflammatory diseases including asthma, and suggests a link between intracranial LTB₄ and neuroendocrine networks. In line with this concept, these inflammatory factors probably have some favourable effects on the HPA axis of asthmatics, and may help to explain the phenomenon of self-relief after an asthmatic attack.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

YMD carried out the experiment design, the western blot, the RT-PCR and the manuscript writing; SJZ carried out the intracerebroventricular injection, lung function measurement, the ACTH and CORT measurement; YLZ and XWD helped to carry out the lung pathological evaluation, the ACTH and CORT measurement and performed the statistical analysis. JXJ helped to run the RT-PCR. QMX conceived and designed this study, and helped to draft the manuscript.

Acknowledgements

This project was supported by the grants from the National Scientific Foundation of China (No. 30671919, 30973542 and 30772581).

Author Details

¹Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, Medical Science College of Zhejiang University, Hangzhou, China and ²Department of Pharmacology, Zhejiang Traditional Chinese Medicine University, Hangzhou, China

Received: 8 October 2009 Accepted: 20 April 2010

Published: 20 April 2010

References

1. Frieri M: **Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases.** *Ann Allergy Asthma Immunol* 2003, **90**:34-40.
2. Borghetti P, Saleri R, Mocchegiani E, Corradi A, Martelli P: **Infection, immunity and the neuroendocrine response.** *Vet Immunol Immunopathol* 2009, **130**:141-62.
3. Berczi I, Quintanar-Stephano A, Kovacs K: **Neuroimmune regulation in immunocompetence, acute illness, and healing.** *Ann N Y Acad Sci* 2009, **1153**:220-39.
4. Sternberg EM: **Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens.** *Nat Rev Immunol* 2006, **6**:318-28.
5. Kelley KW, Weigent DA, Kooijman R: **Protein hormones and immunity.** *Brain Behav Immun* 2007, **21**:384-92.
6. Elenkov IJ: **Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being.** *Neurochem Int* 2008, **52**:40-51.
7. Peters-Golden M, Henderson WR Jr: **Leukotrienes.** *N Engl J Med* 2007, **357**:1841-54.
8. Bernardini R, Chiarenza A, Calogero AE, Gold PW, Chrousos GP: **Arachidonic acid metabolites modulate rat hypothalamic corticotropin-releasing hormone secretion in vitro.** *Neuroendocrinology* 1989, **50**:708-15.
9. Chrousos GP: **The hypothalamic-pituitary-adrenal axis and immunemediated inflammation.** *N Engl J Med* 1995, **332**:1351-1362.
10. Xie QM, Chen JQ, Shen WH, Yang QH, Bian RL: **Comparison of bronchodilating and anti-inflammatory activities of oral formoterol and its (R,R)-enantiomers.** *Acta Pharmacol Sin* 2003, **24**:277-82.
11. Deng YM, Xie QM, Chen JQ, Bian RL: **Coincidental increase of leukotriene B₄ between cerebral cortex and lung tissue of sensitized rats.** *Acta Pharmacol Sin* 2003, **24**:1039-44.
12. Deng YM, Xie QM, Zhang SJ, Chen JQ, Yang QH, Bian RL: **Changes of 5-lipoxygenase pathway and proinflammatory mediators in cerebral**

- cortex and lung tissue of sensitized rats. *Acta Pharmacol Sin* 2005, **26**:353-8.
13. Mauser PJ, Edelman NH, Chapman RW: **Central nervous system control of airway tone in guinea pigs: the role of histamine.** *J Appl Physiol* 1988, **65**:2024-9.
 14. Xie QM, Wu X, Wu HM, Deng YM, Zhang SJ, Zhu JP: **Oral administration of allergen extracts from Dermatophagoides farinae desensitizes specific allergen-induced inflammation and airway hyperresponsiveness in rats.** *Int Immunopharmacol* 2008, **8**:1639-45.
 15. Duan W, Chan JH, Wong CH, Leung BP, Wong WS: **Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.** *J Immunol* 2004, **172**:7053-9.
 16. Meloni EG, Jackson AV, Cohen BM, Carlezon WA Jr: **Corticotropin-releasing factor from the rat brain measured by protein immunoblot.** *Peptides* 2005, **26**:2252-2256.
 17. Callewaere C, Banisadr G, Rostene W, Parsadaniantz SM: **Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation.** *J Mol Endocrinol* 2007, **38**:355-63.
 18. Mocchegiani E, Santarelli L, Costarelli L, Cipriano C, Muti E, Giacconi R, Malavolta M: **Plasticity of neuroendocrine-thymus interactions during ontogeny and ageing: role of zinc and arginine.** *Ageing Res Rev* 2006, **5**:281-309.
 19. Matsumoto I, Inoue Y, Shimada T, Aikawa T: **Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs.** *J Exp Med* 2001, **194**:71-8.
 20. Kalogeromitros D, Syrigou EK, Makris M, Kempuraj D, Stavrianeas NG, Vasiadi M, Theoharides TC: **Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis.** *Ann Allergy Asthma Immunol* 2007, **98**:269-73.
 21. O'Kane M, Murphy EP, Kirby B: **The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease.** *Exp Dermatol* 2006, **15**:143-53.
 22. Silverman ES, Breault DT, Vallone J, Subramanian S, Yilmaz AD, Mathew S, Subramanian V, Tantisira K, Pacak K, Weiss ST, Majzoub JA: **Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma.** *J Allergy Clin Immunol* 2004, **114**:747-754.
 23. Priftis KN, Papadimitriou A, Nicolaidou P, Chrousos GP: **Dysregulation of the stress response in asthmatic children.** *Allergy* 2009, **64**:18-31.
 24. Hallstrand TS, Henderson WR Jr: **An update on the role of leukotrienes in asthma.** *Curr Opin Allergy Clin Immunol* 2010, **10**:60-6.
 25. Yokomizo T, Izumi T, Chang K, Takawa Y, Shimizu T: **A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.** *Nature* 1997, **387**:620-624.
 26. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T: **A new therapeutic target in inflammation and immunological disorders.** *J Exp Med* 2000, **192**:421-432.
 27. Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba SG, Siggins GR, Piomelli D: **Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling.** *J Neurochem* 1996, **66**:147-52.
 28. Matsuo M, Hamasaki Y, Fujiyama F, Miyazaki S: **Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures.** *Brain Res* 1995, **685**:201-4.
 29. Joachim RA, Quarcoo D, Arck PC, Herz U, Renz H, Klapp BF: **Stress enhances airway reactivity and airway inflammation in an animal model of allergic bronchial asthma.** *Psychosom* 2003, **65**:811-815.
 30. Joachim RA, Sagach V, Quarcoo D, Dinh T, Arck PC, Klapp BF: **Upregulation of tumor necrosis factor-alpha by stress and substance p in a murine model of allergic airway inflammation.** *Neuroimmunomodulation* 2006, **13**:43-50.
 31. Forsythe P, Ebeling C, Gordon JR, Befus AD, Vliagoftis H: **Opposing effects of short- and long-term stress on airway inflammation.** *Am J Respir Crit Care Med* 2004, **169**:220-226.

doi: 10.1186/1465-9921-11-39

Cite this article as: Zhang *et al.*, Intracerebroventricular injection of leukotriene B4 attenuates antigen-induced asthmatic response via BLT1 receptor stimulating HPA-axis in sensitized rats *Respiratory Research* 2010, **11**:39

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

